Cabaletta Bio Inc CABA

$2.01 -0.06 (-2.90%)

Valuation

Market cap
350,958,000
Revenue TTM
$0
Net income TTM
$-167,860,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
2,833,116
Avg volume
4,578,858
Day's range
$1.99 – $2.07
Shares out
169,545,000
Stochastic %K
2%
Beta
3.27
Analysts
Strong Sell
Price target
$13.25

Price

Company profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated...

Show more

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
267 759 3100
Website
https://www.cabalettabio.com
Address
2929 Arch Street, Suite 600, Philadelphia, United States

Latest news

Stocktwits

nticoe Sep 28, 5:20 PM
$CABA the question here. They have cash of 350m and the market cap is 350m. Aren't they adding zero value to what ever they have build. 🙄🙄🙄
1 replies
Achandler787 Sep 28, 5:18 PM
$CABA cmon ! $XBI, $FATE , $KYTX sll up!! Take your 35 million shares short and cash in already! Hogs get slaughtered short too!
0 replies
sethgrace Sep 28, 4:15 PM
$CABA Whether your shares can be lent to short sellers depends primarily on your broker's securities lending policies and whether your shares are held in a margin account or lending program. Simply placing an extremely high Good-Til-Cancelled sell order generally does not reliably prevent share lending across all brokers. This myth has circulated on internet forums for years.
0 replies
Jackswac Sep 28, 3:45 PM
$CABA this is trading at cash value at this price level Set your orders to sell good till cancel high above $3 so shorts can't borrow your shares
0 replies
ABDULMOHSEN08 Sep 28, 3:43 PM
$CABA I guarantee you, this is the bottom 🤣🤣🤣
2 replies
sethgrace Sep 28, 3:35 PM
$CABA we made it to the promised land! $2. 🎉
0 replies
venice868 Sep 28, 3:27 PM
$CABA 2 already .. will Caba retest the bottom 1.4?
0 replies
MiroslavBroz Sep 28, 3:23 PM
$CABA Added 2.00
0 replies